Literature DB >> 1532716

Reduced incidence of insulitis in NOD mice following anti-CD3 injection: requirement for neonatal injection.

A R Hayward1, M Shriber.   

Abstract

The incidence of diabetes in NOD mice is reduced following a single neonatal injection of the anti-CD3 antibody, 145.2C11. We now show that the reduction in incidence is greater when the antibody is given in the first than in the third week of life. Anti-CD3 antibody injected in macro-aggregated form did not protect the recipients from insulitis and protection was diminished when elimination of the antibody was accelerated by injecting anti-hamster IgG. Protection was not reversed when anti-CD3 injection was followed by anti-CD4 and anti-CD8. Animals neonatally injected with anti-CD3 were not protected from the induction of diabetes following transfer of spleen cells from diabetic donors. These results contrast with the view that anti-CD3-mediated protection from diabetes depends on a long-lived change in recipient T cells. The findings are consistent with immunosuppression alone being an adequate explanation for the effect of anti-CD3 antibody on susceptibility to diabetes in NOD mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532716     DOI: 10.1016/s0896-8411(05)80051-4

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

Review 1.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

2.  Differential response of regulatory and conventional CD4⁺ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action?

Authors:  Li Li; Junko Nishio; André van Maurik; Diane Mathis; Christophe Benoist
Journal:  J Immunol       Date:  2013-08-28       Impact factor: 5.422

Review 3.  Thinking bedside at the bench: the NOD mouse model of T1DM.

Authors:  James C Reed; Kevan C Herold
Journal:  Nat Rev Endocrinol       Date:  2015-01-27       Impact factor: 43.330

4.  The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse.

Authors:  L Shoda; H Kreuwel; K Gadkar; Y Zheng; C Whiting; M Atkinson; J Bluestone; D Mathis; D Young; S Ramanujan
Journal:  Clin Exp Immunol       Date:  2010-05-18       Impact factor: 4.330

5.  Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints.

Authors:  Junko Nishio; Markus Feuerer; Jamie Wong; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.